PharmTech News

Articles

Paul Hudson, formerly CEO of Novartis Pharmaceuticals, has been tapped to succeed Olivier Brandicourt as CEO of Sanofi.

Former Novartis Pharma Business Head Takes on CEO Mantle at Sanofi

A US District Judge in the Southern District of Florida held that the US Stem Cell Clinic of Weston, FL and US Stem Cell of Sunrise, FL adulterated and misbranded a stem cell drug product made from a patient’s adipose tissue.

Federal Court Decides US Stem Cell Clinics Adulterated and Misbranded Products

The company says it will work with payers to create payment options for its recently approved gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), priced at $2.125 million.

Novartis’ AveXis Prices Zolgensma Gene Therapy at $2+ Million, Offers Access Programs for US Payers and Families

The agency has approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy to treat pediatric spinal muscular atrophy.

FDA OKs Gene Therapy for Pediatric Spinal Muscular Atrophy

The acquisition will expand Pfizer’s rare disease portfolio with an early pipeline candidate for treating dwarfism.

Pfizer to Acquire Biotech Firm Therachon in Deal Worth $810 Million

Novartis will acquire assets associated with Takeda Pharmaceuticals’ Xiidra (lifitegrast ophthalmic solution) 5%, an eye-care drug.

Novartis to Acquire Takeda Eye-Care Drug in Deal Worth Up to $5.3 Billion

Sandoz’s new CEO will assume responsibilities no later than Aug. 1, 2019.

Novartis Appoints New Sandoz CEO

Catalent’s acquisition of Paragon Bioservices will provide expertise and in expanding gene and cell therapy markets.

Catalent to Acquire Paragon Bioservices for $1.2 Billion

With the spin-off, Alcon will operate as a standalone company, and Novartis will focus on its core innovative medicines.

Novartis Completes Alcon Eye-Care Spin-Off

Amgen issued a notice of termination of its migraine collaboration agreements with Novartis, against which Novartis filed a lawsuit in response.

Top News